Dashboard
Manage Tickers

FATE FATE THERAPEUTICS INC

Nasdaq fatetherapeutics.com


$ 0.99 $ -0.03 (-2.85 %)    

Friday, 14-Nov-2025 15:54:46 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 0.964
$ 0.99
$ 0.99 x 1,122
$ 1.00 x 309
$ 0.96 - $ 1.04
$ 0.66 - $ 3.50
2,845,208
na
111.2M
$ 2.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-05-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-26-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-03-2023 03-31-2023 10-Q
12 02-28-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-03-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-04-2021 06-30-2021 10-Q
19 05-05-2021 03-31-2021 10-Q
20 02-24-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-05-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-02-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 03-05-2019 12-31-2018 10-K
29 11-01-2018 09-30-2018 10-Q
30 08-06-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-05-2018 12-31-2017 10-K
33 11-01-2017 09-30-2017 10-Q
34 08-14-2017 06-30-2017 10-Q
35 05-15-2017 03-31-2017 10-Q
36 03-16-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-08-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 03-03-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fate-therapeutics-q3-eps-027-beats-029-estimate-sales-1741m-beat-1535m-estimate
Fate Therapeutics Q3 EPS $(0.27) Beats $(0...
11/13/2025 13:41:22

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0...

hc-wainwright--co-upgrades-fate-therapeutics-to-buy-maintains-price-target-to-5
HC Wainwright & Co. Upgrades Fate Therapeu...
10/31/2025 10:54:45

HC Wainwright & Co. analyst Robert Burns upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Buy and maintains the ...

wedbush-upgrades-fate-therapeutics-to-outperform-raises-price-target-to-7
Wedbush Upgrades Fate Therapeutics to Outp...
10/27/2025 12:40:03

Wedbush analyst David Nierengarten upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Outperform and raises the price ...

needham-reiterates-hold-on-fate-therapeuticsto-hold
Needham Reiterates Hold on Fate Therapeuti...
10/27/2025 09:40:54

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) from Hold to Hold.

reported-sunday-fate-therapeutics-presents-ft819-phase-1-data-demonstrating-immune-remodeling-and-durable-responses-in-10-patients-with-systemic-lupus-erythematosus
Reported Sunday, Fate Therapeutics Present...
10/27/2025 06:37:45

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythema...

fate-therapeutics-appoints-kamal-adawi-as-cfo-effective-october-20
Fate Therapeutics Appoints Kamal Adawi As ...
10/14/2025 12:05:04

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 17:06:34

wells-fargo-maintains-equal-weight-on-fate-therapeutics-lowers-price-target-to-25
Wells Fargo Maintains Equal-Weight on Fate...
08/13/2025 12:52:11

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from...

fate-therapeutics-q2-eps-029-beats-034-estimate-sales-1907m-beat-1011m-estimate
Fate Therapeutics Q2 EPS $(0.29) Beats $(0...
08/12/2025 20:17:59

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0...

needham-reiterates-hold-on-fate-therapeuticsto-hold
Needham Reiterates Hold on Fate Therapeuti...
06/12/2025 12:27:54

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) from Hold to Hold.

fate-therapeutics-announces-new-and-updated-clinical-data-from-first-five-patients-dosed-with-ft819-for-treatment-of-moderate-to-severe-sle-at-eular-2025-congress
Fate Therapeutics Announces New And Update...
06/11/2025 13:02:32

All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primar...

fate-therapeutics-reveals-phase-1-data-presentation-of-ft819-off-the-shelf-car-t-cell-product-candidate-for-sle-at-eular-2025-congress
Fate Therapeutics Reveals Phase 1 Data Pre...
05/28/2025 21:56:24

barclays-maintains-overweight-on-fate-therapeutics-lowers-price-target-to-2
Barclays Maintains Overweight on Fate Ther...
05/14/2025 14:56:43

Barclays analyst Peter Lawson maintains Fate Therapeutics (NASDAQ:FATE) with a Overweight and lowers the price target from $...

4-analysts-assess-fate-therapeutics-what-you-need-to-know
4 Analysts Assess Fate Therapeutics: What ...
05/14/2025 14:00:41

baird-maintains-neutral-on-fate-therapeutics-lowers-price-target-to-4
Baird Maintains Neutral on Fate Therapeuti...
05/14/2025 13:14:28

Baird analyst Jack Allen maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the price target from $5 to $4.

needham-reiterates-hold-on-fate-therapeuticsto-hold
Needham Reiterates Hold on Fate Therapeuti...
05/14/2025 11:31:55

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) from Hold to Hold.

fate-therapeutics-q1-eps-032-beats-038-estimate-sales-163m-beat-114m-estimate
Fate Therapeutics Q1 EPS $(0.32) Beats $(0...
05/13/2025 20:12:11

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0...

fate-therapeutics-wins-regenerative-medicine-advanced-therapy-designation-from-fda-for-ft819-to-treat-moderate-to-severe-systemic-lupus-erythematosus
Fate Therapeutics Wins Regenerative Medici...
04/14/2025 12:05:22

–   Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue w...

stifel-maintains-hold-on-fate-therapeutics-lowers-price-target-to-3
Stifel Maintains Hold on Fate Therapeutics...
03/06/2025 15:59:11

Stifel analyst Benjamin Burnett maintains Fate Therapeutics (NASDAQ:FATE) with a Hold and lowers the price target from $5 to...

wedbush-reiterates-neutral-on-fate-therapeutics-maintains-5-price-target
Wedbush Reiterates Neutral on Fate Therape...
03/06/2025 14:10:44

Wedbush analyst David Nierengarten reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $5 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION